<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286558</url>
  </required_header>
  <id_info>
    <org_study_id>1235.37</org_study_id>
    <nct_id>NCT01286558</nct_id>
  </id_info>
  <brief_title>Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)</brief_title>
  <official_title>An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80mg Plus Amlodipine 5 mg Fixed-dose Combination vs. Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination in Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Blood pressure in hypertensive patients is rarely controlled to an optimal level by one drug
      alone, often a combination of two or more drugs is essential to achieve a sufficient
      antihypertensive effect. Therefore in Japanese Society of Hypertension (JSH) 2009 combination
      therapy is recommended. In JSH 2009 it is advised to start the combination therapy at a low
      dose, and to increase the dosage when the antihypertensive effect is not sufficient. In the
      Japanese long-term safety study, 259 patients received the T40/A5 mg fixed-dose combination
      (FDC), and after 6 weeks treatment 48 patients of them could not control their blood pressure
      (DBP =90) (U09-2494-01). For those patients who cannot control their blood pressure with
      T40/A5 mg FDC, a switch to a higher dose such as T80/A5 mg is recommended.

      In the overseas 4x4 factorial design trial, a clinically meaningful difference of the blood
      pressure lowering effect between T80/A5 mg free combination and T40/A5 mg free combination
      was shown (U07-3503-02). But the sponsor has no data that verifies this difference in
      Japanese patients.

      Thus, this clinical trial is being conducted to investigate the antihypertensive effect and
      safety of high dose T80/A5 mg FDC compared with low dose T40/A5 mg FDC in Japanese patients
      with essential hypertension. In this trial, a multi-centre, randomised, double-blind,
      double-dummy, active-controlled, parallel group comparison method is employed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough</measure>
    <time_frame>Reference baseline, 8 weeks</time_frame>
    <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough</measure>
    <time_frame>Reference baseline, 8 weeks</time_frame>
    <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From the Reference Baseline in the 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean (Relative to Dose Time) for DBP</measure>
    <time_frame>Reference baseline, 8 weeks</time_frame>
    <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From the Reference Baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP</measure>
    <time_frame>Reference baseline, 8 weeks</time_frame>
    <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for DBP</measure>
    <time_frame>Pseudo-baseline, 14 weeks</time_frame>
    <description>Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP</measure>
    <time_frame>Pseudo-baseline, 14 weeks</time_frame>
    <description>Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From the Reference Baseline in DBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM</measure>
    <time_frame>Reference baseline, 8 weeks</time_frame>
    <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From the Reference Baseline in SBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM</measure>
    <time_frame>Reference baseline, 8 weeks</time_frame>
    <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated DBP Control Rate at Trough</measure>
    <time_frame>8 weeks</time_frame>
    <description>DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated SBP Control Rate at Trough</measure>
    <time_frame>8 weeks</time_frame>
    <description>SBP control rate: The rate of patients with controlled seated DBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated DBP Response Rate at Trough</measure>
    <time_frame>8 weeks</time_frame>
    <description>DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (&lt;90 mmHg and/or reduction from reference baseline &gt;=10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated SBP Response Rate at Trough</measure>
    <time_frame>8 weeks</time_frame>
    <description>SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (&lt;140 mmHg and/or reduction from reference baseline &gt;=20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated Blood Pressure (BP) Normalisation at Trough</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>80mg telmisartan and 5mg amlodipine FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40mg telmisartan and 5mg amlodipine FDC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 mg telmisartan</intervention_name>
    <description>once daily</description>
    <arm_group_label>40mg telmisartan and 5mg amlodipine FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg amlodipine</intervention_name>
    <description>once daily</description>
    <arm_group_label>80mg telmisartan and 5mg amlodipine FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg amlodipine</intervention_name>
    <description>once daily</description>
    <arm_group_label>40mg telmisartan and 5mg amlodipine FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80 mg telmisartan</intervention_name>
    <description>once daily</description>
    <arm_group_label>80mg telmisartan and 5mg amlodipine FDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Essential hypertensive patients

               -  If already taking antihypertensive drugs, mean seated diastolic blood pressure
                  (DBP) must be &gt;=90 and &gt;=114 mmHg

               -  If not taking any antihypertensive drugs, mean seated DBP must be &gt;=95 and &gt;=114
                  mmHg

          2. Able to stop all current antihypertensive drugs without risk to the patient based on
             the investigators opinion.

        Exclusion criteria:

          1. Patients taking 3 or more antihypertensive drugs at signing the informed consent form

          2. Patients with known or suspected secondary hypertension

          3. Patients with clinically relevant cardiac arrhythmia

          4. Congestive heart failure with New York Heart Association (NYHA) functional class
             III-IV

          5. Patients with recent cardiovascular events

          6. Patients with a history of stroke or transient ischaemic attack within last 6 months
             before signing the informed consent form

          7. Patients with a history of sudden deterioration of renal function with angiotensin II
             receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or
             patients with post-renal transplant or post-nephrectomy

          8. Patients who have previously experienced characteristic symptoms of angioedema (such
             as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment
             with ARBs or ACE inhibitors

          9. Patients with known hypersensitivity to any component of the investigational product,
             or a known hypersensitivity to dihydropyridine-derived drugs

         10. Patients with hepatic and/or renal dysfunction

         11. Pre-menopausal women who are nursing or pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.37.01 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.37.07 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hiroshima, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.37.08 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itoshima, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.37.02 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Katsushika-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.37.05 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.37.03 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ota-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.37.06 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.37.04 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2011</study_first_submitted>
  <study_first_submitted_qc>January 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <results_first_submitted>September 20, 2012</results_first_submitted>
  <results_first_submitted_qc>September 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2012</results_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
        </group>
        <group group_id="P2">
          <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
        </group>
        <group group_id="B2">
          <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="112"/>
            <count group_id="B2" value="113"/>
            <count group_id="B3" value="225"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="8.4"/>
                    <measurement group_id="B2" value="52.8" spread="9.4"/>
                    <measurement group_id="B3" value="53.7" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough</title>
        <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing</description>
        <time_frame>Reference baseline, 8 weeks</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
          <group group_id="O2">
            <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
        </group_list>
        <measure>
          <title>Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough</title>
          <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing</description>
          <population>Full analysis set (FAS)</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="0.61"/>
                    <measurement group_id="O2" value="3.47" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>3.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough</title>
        <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing</description>
        <time_frame>Reference baseline, 8 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
          <group group_id="O2">
            <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
        </group_list>
        <measure>
          <title>Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough</title>
          <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing</description>
          <population>FAS</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" spread="0.90"/>
                    <measurement group_id="O2" value="3.41" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>4.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From the Reference Baseline in the 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean (Relative to Dose Time) for DBP</title>
        <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
        <time_frame>Reference baseline, 8 weeks</time_frame>
        <population>ABPM set, i.e., a subset of FAS and with patients who had available ABPM measurements</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
          <group group_id="O2">
            <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
        </group_list>
        <measure>
          <title>Changes From the Reference Baseline in the 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean (Relative to Dose Time) for DBP</title>
          <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
          <population>ABPM set, i.e., a subset of FAS and with patients who had available ABPM measurements</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.54" spread="0.49"/>
                    <measurement group_id="O2" value="-0.33" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.58</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From the Reference Baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP</title>
        <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
        <time_frame>Reference baseline, 8 weeks</time_frame>
        <population>ABPM set, i.e., a subset of FAS and with patients who had available ABPM measurements</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
          <group group_id="O2">
            <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
        </group_list>
        <measure>
          <title>Changes From the Reference Baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP</title>
          <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
          <population>ABPM set, i.e., a subset of FAS and with patients who had available ABPM measurements</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.81" spread="0.81"/>
                    <measurement group_id="O2" value="-0.91" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.16</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for DBP</title>
        <description>Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
        <time_frame>Pseudo-baseline, 14 weeks</time_frame>
        <population>ABPM set, i.e., a subset of FAS and with patients who had available ABPM measurements</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
          <group group_id="O2">
            <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
        </group_list>
        <measure>
          <title>Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for DBP</title>
          <description>Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
          <population>ABPM set, i.e., a subset of FAS and with patients who had available ABPM measurements</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.16" spread="0.61"/>
                    <measurement group_id="O2" value="-11.28" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.57</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP</title>
        <description>Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
        <time_frame>Pseudo-baseline, 14 weeks</time_frame>
        <population>ABPM set, i.e., a subset of FAS and with patients who had available ABPM measurements</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
          <group group_id="O2">
            <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
        </group_list>
        <measure>
          <title>Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP</title>
          <description>Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
          <population>ABPM set, i.e., a subset of FAS and with patients who had available ABPM measurements</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.96" spread="0.96"/>
                    <measurement group_id="O2" value="-19.32" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.27</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From the Reference Baseline in DBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM</title>
        <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
        <time_frame>Reference baseline, 8 weeks</time_frame>
        <population>ABPM set, i.e., a subset of FAS and with patients who had available ABPM measurements</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
          <group group_id="O2">
            <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
        </group_list>
        <measure>
          <title>Changes From the Reference Baseline in DBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM</title>
          <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
          <population>ABPM set, i.e., a subset of FAS and with patients who had available ABPM measurements</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.04" spread="10.27"/>
                    <measurement group_id="O2" value="-0.22" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="11.44"/>
                    <measurement group_id="O2" value="0.32" spread="10.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="11.86"/>
                    <measurement group_id="O2" value="2.87" spread="11.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.69" spread="12.43"/>
                    <measurement group_id="O2" value="-0.02" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="13.22"/>
                    <measurement group_id="O2" value="-0.75" spread="14.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="11.08"/>
                    <measurement group_id="O2" value="-0.86" spread="13.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="12.24"/>
                    <measurement group_id="O2" value="-1.25" spread="13.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="13.23"/>
                    <measurement group_id="O2" value="0.55" spread="13.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.77" spread="12.83"/>
                    <measurement group_id="O2" value="-0.73" spread="12.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.80" spread="13.75"/>
                    <measurement group_id="O2" value="-0.14" spread="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="11.58"/>
                    <measurement group_id="O2" value="-1.16" spread="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="11.86"/>
                    <measurement group_id="O2" value="-1.43" spread="13.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.33" spread="12.96"/>
                    <measurement group_id="O2" value="-1.05" spread="12.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="15.49"/>
                    <measurement group_id="O2" value="-0.08" spread="11.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="13.65"/>
                    <measurement group_id="O2" value="1.86" spread="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="10.73"/>
                    <measurement group_id="O2" value="0.85" spread="10.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="12.16"/>
                    <measurement group_id="O2" value="-0.80" spread="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.89" spread="11.81"/>
                    <measurement group_id="O2" value="1.02" spread="10.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.12" spread="12.96"/>
                    <measurement group_id="O2" value="0.10" spread="10.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="11.03"/>
                    <measurement group_id="O2" value="-1.27" spread="11.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" spread="12.85"/>
                    <measurement group_id="O2" value="-0.90" spread="10.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="11.83"/>
                    <measurement group_id="O2" value="-1.67" spread="13.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.07" spread="12.05"/>
                    <measurement group_id="O2" value="-0.53" spread="11.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="9.37"/>
                    <measurement group_id="O2" value="0.42" spread="11.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From the Reference Baseline in SBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM</title>
        <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
        <time_frame>Reference baseline, 8 weeks</time_frame>
        <population>ABPM set, i.e., a subset of FAS and with patients who had available ABPM measurements</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
          <group group_id="O2">
            <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
        </group_list>
        <measure>
          <title>Changes From the Reference Baseline in SBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM</title>
          <description>Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined</description>
          <population>ABPM set, i.e., a subset of FAS and with patients who had available ABPM measurements</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.54" spread="16.03"/>
                    <measurement group_id="O2" value="-1.78" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.78" spread="14.98"/>
                    <measurement group_id="O2" value="-0.28" spread="15.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.41" spread="16.83"/>
                    <measurement group_id="O2" value="2.72" spread="17.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.72" spread="18.42"/>
                    <measurement group_id="O2" value="-1.88" spread="17.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="18.23"/>
                    <measurement group_id="O2" value="-2.54" spread="20.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="18.39"/>
                    <measurement group_id="O2" value="-2.48" spread="20.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="19.12"/>
                    <measurement group_id="O2" value="-2.45" spread="18.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.05" spread="20.40"/>
                    <measurement group_id="O2" value="-0.27" spread="22.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.09" spread="17.35"/>
                    <measurement group_id="O2" value="-1.17" spread="18.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.78" spread="19.61"/>
                    <measurement group_id="O2" value="-0.70" spread="18.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="19.59"/>
                    <measurement group_id="O2" value="0.69" spread="15.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.57" spread="17.54"/>
                    <measurement group_id="O2" value="0.61" spread="16.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" spread="19.90"/>
                    <measurement group_id="O2" value="0.26" spread="17.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="21.12"/>
                    <measurement group_id="O2" value="-1.09" spread="17.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="17.86"/>
                    <measurement group_id="O2" value="1.41" spread="17.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="17.18"/>
                    <measurement group_id="O2" value="0.68" spread="15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="17.58"/>
                    <measurement group_id="O2" value="-1.16" spread="15.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.66" spread="18.90"/>
                    <measurement group_id="O2" value="1.01" spread="15.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.58" spread="18.92"/>
                    <measurement group_id="O2" value="-1.24" spread="15.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="19.07"/>
                    <measurement group_id="O2" value="-3.56" spread="17.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.02" spread="17.27"/>
                    <measurement group_id="O2" value="-1.20" spread="16.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.88" spread="16.81"/>
                    <measurement group_id="O2" value="-4.12" spread="17.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.65" spread="21.01"/>
                    <measurement group_id="O2" value="-2.71" spread="16.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="16.51"/>
                    <measurement group_id="O2" value="0.29" spread="16.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seated DBP Control Rate at Trough</title>
        <description>DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing</description>
        <time_frame>8 weeks</time_frame>
        <population>Patients included in FAS and with seated DBP &gt;=90 mmHg at reference baseline</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
          <group group_id="O2">
            <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
        </group_list>
        <measure>
          <title>Seated DBP Control Rate at Trough</title>
          <description>DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing</description>
          <population>Patients included in FAS and with seated DBP &gt;=90 mmHg at reference baseline</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1"/>
                    <measurement group_id="O2" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                    <measurement group_id="O2" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seated SBP Control Rate at Trough</title>
        <description>SBP control rate: The rate of patients with controlled seated DBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing</description>
        <time_frame>8 weeks</time_frame>
        <population>Patients included in FAS and with seated SBP &gt;=140 mmHg at reference baseline</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
          <group group_id="O2">
            <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
        </group_list>
        <measure>
          <title>Seated SBP Control Rate at Trough</title>
          <description>SBP control rate: The rate of patients with controlled seated DBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing</description>
          <population>Patients included in FAS and with seated SBP &gt;=140 mmHg at reference baseline</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2"/>
                    <measurement group_id="O2" value="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8"/>
                    <measurement group_id="O2" value="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seated DBP Response Rate at Trough</title>
        <description>DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (&lt;90 mmHg and/or reduction from reference baseline &gt;=10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
          <group group_id="O2">
            <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
        </group_list>
        <measure>
          <title>Seated DBP Response Rate at Trough</title>
          <description>DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (&lt;90 mmHg and/or reduction from reference baseline &gt;=10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                    <measurement group_id="O2" value="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5"/>
                    <measurement group_id="O2" value="67.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seated SBP Response Rate at Trough</title>
        <description>SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (&lt;140 mmHg and/or reduction from reference baseline &gt;=20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
          <group group_id="O2">
            <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
        </group_list>
        <measure>
          <title>Seated SBP Response Rate at Trough</title>
          <description>SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (&lt;140 mmHg and/or reduction from reference baseline &gt;=20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6"/>
                    <measurement group_id="O2" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4"/>
                    <measurement group_id="O2" value="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seated Blood Pressure (BP) Normalisation at Trough</title>
        <description>Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
          <group group_id="O2">
            <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
          </group>
        </group_list>
        <measure>
          <title>Seated Blood Pressure (BP) Normalisation at Trough</title>
          <description>Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration in the double-blind treatment period until 24 hours after the last dose, up to 69 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>80 mg Telmisartan and 5 mg Amlodipine FDC</title>
        </group>
        <group group_id="E2">
          <title>40 mg Telmisartan and 5 mg Amlodipine FDC</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

